Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S

Published Apr 06 2021 at 10:00 PM GMT

Stats

  • Published Apr 6, 2021 10:00 PM GMT